{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T15:07:03Z","timestamp":1790003223246,"version":"4.0.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,6,30]],"date-time":"2021-06-30T00:00:00Z","timestamp":1625011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,6,30]],"date-time":"2021-06-30T00:00:00Z","timestamp":1625011200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004896","name":"Eisai Inc.","doi-asserted-by":"crossref","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/501100004896","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Eribulin mesylate (ERI; Halaven\u00ae) is a microtubule inhibitor approved in the United States for metastatic breast cancer patients with at least two prior chemotherapy regimens for metastatic breast cancer, and in the European Union in locally advanced breast cancer or metastatic breast cancer patients who progressed after at least one chemotherapy for advanced disease. This network meta-analysis compared the efficacy and safety of ERI versus other chemotherapies in this setting.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Systematic searches conducted in MEDLINE, Embase, and the Cochrane Central Register of Clinical Trials identified randomized controlled trials of locally advanced breast cancer\/metastatic breast cancer chemotherapies in second- or later-line settings. Efficacy assessment included pre-specified subgroup analysis of breast cancer subtypes. Included studies were assessed for quality using the Centre for Reviews and Dissemination tool. Bayesian network meta-analysis estimated primary outcomes of overall survival and progression-free survival using fixed-effect models. Comparators included: capecitabine (CAP), gemcitabine (GEM), ixabepilone (IXA), utidelone (UTI), treatment by physician\u2019s choice (TPC), and vinorelbine (VIN).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The network meta-analysis included seven trials. Results showed that second- or later-line patients treated with ERI had statistically longer overall survival versus TPC (hazard ratio [HR]: 0.81; credible interval [CrI]: 0.66\u20130.99) or GEM+VIN (0.62; 0.42\u20130.90) and statistically longer progression-free survival versus TPC (0.76; 0.64\u20130.90), but statistically shorter progression-free survival versus CAP+IXA (1.40; 1.17\u20131.67) and CAP+UTI (1.61; 1.23\u20132.12). In triple negative breast cancer, ERI had statistically longer overall survival versus CAP (0.70; 0.54\u20130.90); no statistical differences in progression-free survival were observed in triple negative breast cancer.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>This network meta-analysis suggests that ERI may provide an overall survival benefit in the overall locally advanced breast cancer\/metastatic breast cancer populations and triple negative breast cancer subgroup compared to standard treatments. These findings support the use of ERI in second- or later-line treatment of patients with locally advanced breast cancer\/metastatic breast cancer.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12885-021-08446-8","type":"journal-article","created":{"date-parts":[[2021,6,30]],"date-time":"2021-06-30T11:04:26Z","timestamp":1625051066000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Network meta-analysis of eribulin versus other chemotherapies used as second- or later-line treatment in locally advanced or metastatic breast cancer"],"prefix":"10.1186","volume":"21","author":[{"given":"Qi","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Hughes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Binod","family":"Neupane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin","family":"Mickle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Chabot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marissa","family":"Betts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5669-4887","authenticated-orcid":false,"given":"Ananth","family":"Kadambi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,6,30]]},"reference":[{"key":"8446_CR1","unstructured":"National Cancer Institute, Surveillance, Epidemiology, and End Results Program (SEER). Cancer Stat Facts: Female Breast Cancer [Available from: https:\/\/ seer.cancer.gov\/statfacts\/html\/breast.html."},{"issue":"3","key":"8446_CR2","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1038\/nrclinonc.2015.13","volume":"12","author":"K Tryfonidis","year":"2015","unstructured":"Tryfonidis K, Senkus E, Cardoso MJ, Cardoso F. Management of locally advanced breast cancer-perspectives and future directions. Nat Rev Clin Oncol. 2015;12(3):147\u201362. https:\/\/doi.org\/10.1038\/nrclinonc.2015.13.","journal-title":"Nat Rev Clin Oncol"},{"issue":"5","key":"8446_CR3","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1093\/annonc\/mdq429","volume":"22","author":"H Roche","year":"2011","unstructured":"Roche H, Vahdat LT. Treatment of metastatic breast cancer: second line and beyond. Ann Oncol. 2011;22(5):1000\u201310. https:\/\/doi.org\/10.1093\/annonc\/mdq429.","journal-title":"Ann Oncol"},{"key":"8446_CR4","volume-title":"Halaven (eribulin): summary of the European public assessment report (EPAR) for Halaven. Last update: Feb 2, 2018","author":"European Medicines Agency (EMA)","year":"2011","unstructured":"European Medicines Agency (EMA). Halaven (eribulin): summary of the European public assessment report (EPAR) for Halaven. Last update: Feb 2, 2018. 2011; http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/human\/medicines\/002084\/human_med_001427.jsp&mid=WC0b01ac058001d124. Accessed June 2018."},{"key":"8446_CR5","unstructured":"Eisai Inc. HALAVEN\u00ae (eribulin mesylate) injection, for intravenous use. Full Prescribing information. Initial U.S. Approval: 2010. Revised: October 2016. 2016; https:\/\/www.halaven.com\/-\/media\/Files\/Halaven\/HALAVEN-Full-Prescribing-Information.pdf. Accessed June 2018."},{"key":"8446_CR6","doi-asserted-by":"publisher","first-page":"21","DOI":"10.2147\/BTT.S19811","volume":"6","author":"S Jain","year":"2012","unstructured":"Jain S, Cigler T. Eribulin mesylate in the treatment of metastatic breast cancer. Biologics. 2012;6:21\u20139. https:\/\/doi.org\/10.2147\/BTT.S19811.","journal-title":"Biologics."},{"issue":"11","key":"8446_CR7","doi-asserted-by":"publisher","first-page":"777","DOI":"10.7326\/M14-2385","volume":"162","author":"B Hutton","year":"2015","unstructured":"Hutton B, Salanti G, Caldwell DM, Chaimani A, Schmid CH, Cameron C, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med. 2015;162(11):777\u201384. https:\/\/doi.org\/10.7326\/M14-2385.","journal-title":"Ann Intern Med"},{"issue":"7","key":"8446_CR8","doi-asserted-by":"publisher","first-page":"e1000100","DOI":"10.1371\/journal.pmed.1000100","volume":"6","author":"A Liberati","year":"2009","unstructured":"Liberati A, Altman DG, Tetzlaff J, Mulrow C, G\u00f8tzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med. 2009;6(7):e1000100. https:\/\/doi.org\/10.1371\/journal.pmed.1000100.","journal-title":"PLoS Med"},{"key":"8446_CR9","unstructured":"National Institute for Health and Care Excellence (NICE). Guide to the methods of technology appraisal 2013. Process and methods (PMG9) [Available from: https:\/\/www.nice.org.uk\/process\/pmg9\/chapter\/foreword."},{"issue":"7521","key":"8446_CR10","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1136\/bmj.331.7521.897","volume":"331","author":"DM Caldwell","year":"2005","unstructured":"Caldwell DM, Ades AE, Higgins JP. Simultaneous comparison of multiple treatments: combining direct and indirect evidence. BMJ. 2005;331(7521):897\u2013900. https:\/\/doi.org\/10.1136\/bmj.331.7521.897.","journal-title":"BMJ."},{"issue":"20","key":"8446_CR11","doi-asserted-by":"publisher","first-page":"3105","DOI":"10.1002\/sim.1875","volume":"23","author":"G Lu","year":"2004","unstructured":"Lu G, Ades AE. Combination of direct and indirect evidence in mixed treatment comparisons. Stat Med. 2004;23(20):3105\u201324. https:\/\/doi.org\/10.1002\/sim.1875.","journal-title":"Stat Med"},{"issue":"6","key":"8446_CR12","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1200\/JCO.2013.52.4892","volume":"33","author":"PA Kaufman","year":"2015","unstructured":"Kaufman PA, Awada A, Twelves C, Yelle L, Perez EA, Velikova G, et al. Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol. 2015;33(6):594\u2013601. https:\/\/doi.org\/10.1200\/JCO.2013.52.4892.","journal-title":"J Clin Oncol"},{"key":"8446_CR13","first-page":"77","volume":"10","author":"C Twelves","year":"2016","unstructured":"Twelves C, Awada A, Cortes J, Yelle L, Velikova G, Olivo MS, et al. Subgroup analyses from a phase 3, open-label, randomized study of eribulin mesylate versus capecitabine in pretreated patients with advanced or metastatic breast cancer. Breast Cancer (Auckl). 2016;10:77\u201384.","journal-title":"Breast Cancer (Auckl)"},{"issue":"3","key":"8446_CR14","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1007\/s10549-015-3633-7","volume":"154","author":"J Cortes","year":"2015","unstructured":"Cortes J, Hudgens S, Twelves C, Perez EA, Awada A, Yelle L, et al. Health-related quality of life in patients with locally advanced or metastatic breast cancer treated with eribulin mesylate or capecitabine in an open-label randomized phase 3 trial. Breast Cancer Res Treat. 2015;154(3):509\u201320. https:\/\/doi.org\/10.1007\/s10549-015-3633-7.","journal-title":"Breast Cancer Res Treat"},{"issue":"3","key":"8446_CR15","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1007\/s12282-017-0826-4","volume":"25","author":"X Pivot","year":"2018","unstructured":"Pivot X, Im SA, Guo M, Marm\u00e9 F. Subgroup analysis of patients with HER2-negative metastatic breast cancer in the second-line setting from a phase 3, open-label, randomized study of eribulin mesilate versus capecitabine. Breast Cancer. 2018;25(3):370\u20134. https:\/\/doi.org\/10.1007\/s12282-017-0826-4.","journal-title":"Breast Cancer"},{"issue":"9769","key":"8446_CR16","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1016\/S0140-6736(11)60070-6","volume":"377","author":"J Cortes","year":"2011","unstructured":"Cortes J, O'Shaughnessy J, Loesch D, Blum JL, Vahdat LT, Petrakova K, et al. Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet. 2011;377(9769):914\u201323. https:\/\/doi.org\/10.1016\/S0140-6736(11)60070-6.","journal-title":"Lancet."},{"key":"8446_CR17","doi-asserted-by":"publisher","unstructured":"Twelves C, Cortes J, Kaufman P, Yelle L, Awada A, Binder T, et al. \u201cNew\u201d metastases are associated with a poorer prognosis than growth of preexisting metastases in patients with metastatic breast cancer treated with chemotherapy. Breast Cancer Res. 2015;17(150).\u00a0https:\/\/doi.org\/10.1186\/s13058-015-0657-1.","DOI":"10.1186\/s13058-015-0657-1"},{"issue":"S332","key":"8446_CR18","doi-asserted-by":"publisher","first-page":"S331","DOI":"10.1016\/S0959-8049(11)71448-4","volume":"47","author":"F Cardoso","year":"2011","unstructured":"Cardoso F, Twelves C, Vahdat L, Dutcus C, Seegobin S, Wanders J, et al. Eribulin mesylate EMBRACE study - survival analysis excluding patients re-challenged with therapies of the same class. Eur J Cancer. 2011;47(S332):S331\u20132. https:\/\/doi.org\/10.1016\/S0959-8049(11)71448-4.","journal-title":"Eur J Cancer"},{"issue":"5","key":"8446_CR19","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1093\/annonc\/mdr405","volume":"23","author":"AG Pallis","year":"2012","unstructured":"Pallis AG, Boukovinas I, Ardavanis A, Varthalitis I, Malamos N, Georgoulias V, et al. A multicenter randomized phase III trial of vinorelbine\/gemcitabine doublet versus capecitabine monotherapy in anthracycline- and taxane-pretreated women with metastatic breast cancer. Ann Oncol. 2012;23(5):1164\u20139. https:\/\/doi.org\/10.1093\/annonc\/mdr405.","journal-title":"Ann Oncol"},{"issue":"2","key":"8446_CR20","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/s10549-013-2574-2","volume":"140","author":"LT Vahdat","year":"2013","unstructured":"Vahdat LT, Garcia AA, Vogel C, Pellegrino C, Lindquist DL, Iannotti N, et al. Eribulin mesylate versus ixabepilone in patients with metastatic breast cancer: a randomized phase II study comparing the incidence of peripheral neuropathy. Breast Cancer Res Treat. 2013;140(2):341\u201351. https:\/\/doi.org\/10.1007\/s10549-013-2574-2.","journal-title":"Breast Cancer Res Treat"},{"issue":"33","key":"8446_CR21","doi-asserted-by":"publisher","first-page":"5210","DOI":"10.1200\/JCO.2007.12.6557","volume":"25","author":"ES Thomas","year":"2007","unstructured":"Thomas ES, Gomez HL, Li RK, Chung HC, Fein LE, Chan VF, et al. Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol. 2007;25(33):5210\u20137. https:\/\/doi.org\/10.1200\/JCO.2007.12.6557.","journal-title":"J Clin Oncol"},{"issue":"2","key":"8446_CR22","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s10549-010-0901-4","volume":"122","author":"GN Hortobagyi","year":"2010","unstructured":"Hortobagyi GN, Gomez HL, Li RK, Chung HC, Fein LE, Chan VF, et al. Analysis of overall survival from a phase III study of ixabepilone plus capecitabine versus capecitabine in patients with MBC resistant to anthracyclines and taxanes. Breast Cancer Res Treat. 2010;122(2):409\u201318. https:\/\/doi.org\/10.1007\/s10549-010-0901-4.","journal-title":"Breast Cancer Res Treat"},{"issue":"6","key":"8446_CR23","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/j.clbc.2018.07.024","volume":"18","author":"HS Rugo","year":"2018","unstructured":"Rugo HS, Roche H, Thomas E, Chung HC, Lerzo GL, Vasyutin I, et al. Efficacy and safety of ixabepilone and capecitabine in patients with advanced triple-negative breast cancer: a pooled analysis from two large phase III, Randomized Clinical Trials. Clin Breast Cancer. 2018;18(6):489\u201397. https:\/\/doi.org\/10.1016\/j.clbc.2018.07.024.","journal-title":"Clin Breast Cancer"},{"issue":"20","key":"8446_CR24","doi-asserted-by":"publisher","first-page":"3256","DOI":"10.1200\/JCO.2009.24.4244","volume":"28","author":"JA Sparano","year":"2010","unstructured":"Sparano JA, Vrdoljak E, Rixe O, Xu B, Manikhas A, Medina C, et al. Randomized phase III trial of ixabepilone plus capecitabine versus capecitabine in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol. 2010;28(20):3256\u201363. https:\/\/doi.org\/10.1200\/JCO.2009.24.4244.","journal-title":"J Clin Oncol"},{"issue":"3","key":"8446_CR25","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/S1470-2045(17)30088-8","volume":"18","author":"P Zhang","year":"2017","unstructured":"Zhang P, Sun T, Zhang Q, Yuan Z, Jiang Z, Wang XJ, et al. Utidelone plus capecitabine versus capecitabine alone for heavily pretreated metastatic breast cancer refractory to anthracyclines and taxanes: a multicentre, open-label, superiority, phase 3, randomised controlled trial. Lancet Oncol. 2017;18(3):371\u201383. https:\/\/doi.org\/10.1016\/S1470-2045(17)30088-8.","journal-title":"Lancet Oncol"},{"issue":"4","key":"8446_CR26","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1177\/096228020101000404","volume":"10","author":"AJ Sutton","year":"2001","unstructured":"Sutton AJ, Abrams KR. Bayesian methods in meta-analysis and evidence synthesis. Stat Methods Med Res. 2001;10(4):277\u2013303. https:\/\/doi.org\/10.1177\/096228020101000404.","journal-title":"Stat Methods Med Res"},{"issue":"1","key":"8446_CR27","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1186\/s13643-015-0133-0","volume":"4","author":"C Cameron","year":"2015","unstructured":"Cameron C, Fireman B, Hutton B, Clifford T, Coyle D, Wells G, et al. Network meta-analysis incorporating randomized controlled trials and non-randomized comparative cohort studies for assessing the safety and effectiveness of medical treatments: challenges and opportunities. Syst Rev. 2015;4(1):147. https:\/\/doi.org\/10.1186\/s13643-015-0133-0.","journal-title":"Syst Rev"},{"issue":"1","key":"8446_CR28","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/s10549-017-4404-4","volume":"166","author":"FR Wilson","year":"2017","unstructured":"Wilson FR, Varu A, Mitra D, Cameron C, Iyer S. Systematic review and network meta-analysis comparing palbociclib with chemotherapy agents for the treatment of postmenopausal women with HR-positive and HER2-negative advanced\/metastatic breast cancer. Breast Cancer Res Treat. 2017;166(1):167\u201377. https:\/\/doi.org\/10.1007\/s10549-017-4404-4.","journal-title":"Breast Cancer Res Treat"},{"key":"8446_CR29","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.ejca.2019.02.002","volume":"112","author":"P Yuan","year":"2019","unstructured":"Yuan P, Hu X, Sun T, Li W, Zhang Q, Cui S, et al. Eribulin mesilate versus vinorelbine in women with locally recurrent or metastatic breast cancer: a randomised clinical trial. Eur J Cancer. 2019;112:57\u201365. https:\/\/doi.org\/10.1016\/j.ejca.2019.02.002.","journal-title":"Eur J Cancer"},{"issue":"11","key":"8446_CR30","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1634\/theoncologist.2012-0161","volume":"17","author":"C Palmieri","year":"2012","unstructured":"Palmieri C, Alifrangis C, Shipway D, Tat T, Watson V, Mackie D, et al. A randomized feasibility study of docetaxel versus vinorelbine in advanced breast cancer. Oncologist. 2012;17(11):1429\u2013e47. https:\/\/doi.org\/10.1634\/theoncologist.2012-0161.","journal-title":"Oncologist."},{"issue":"3\u20134","key":"8446_CR31","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1159\/000236021","volume":"77","author":"CA Papadimitriou","year":"2009","unstructured":"Papadimitriou CA, Kalofonos H, Zagouri F, Papakostas P, Bozas G, Makatsoris T, et al. Weekly docetaxel with or without gemcitabine as second-line chemotherapy in paclitaxel-pretreated patients with metastatic breast cancer: a randomized phase II study conducted by the Hellenic co-operative oncology group. Oncology. 2009;77(3\u20134):212\u20136. https:\/\/doi.org\/10.1159\/000236021.","journal-title":"Oncology."},{"issue":"11","key":"8446_CR32","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1200\/JCO.2007.15.8485","volume":"27","author":"S Chan","year":"2009","unstructured":"Chan S, Romieu G, Huober J, Delozier T, Tubiana-Hulin M, Schneeweiss A, et al. Phase III study of gemcitabine plus docetaxel compared with capecitabine plus docetaxel for anthracycline-pretreated patients with metastatic breast cancer. J Clin Oncol. 2009;27(11):1753\u201360. https:\/\/doi.org\/10.1200\/JCO.2007.15.8485.","journal-title":"J Clin Oncol"},{"key":"8446_CR33","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.breast.2019.01.009","volume":"45","author":"M Aapro","year":"2019","unstructured":"Aapro M, Ruiz-Borrego M, Hegg R, Kukielka-Budny B, Morales S, Cinieri S, et al. Randomized phase II study evaluating weekly oral vinorelbine versus weekly paclitaxel in estrogen receptor-positive, HER2-negative patients with advanced breast cancer (NorBreast-231 trial). Breast. 2019;45:7\u201314. https:\/\/doi.org\/10.1016\/j.breast.2019.01.009.","journal-title":"Breast."},{"issue":"5","key":"8446_CR34","doi-asserted-by":"publisher","first-page":"e919","DOI":"10.1016\/j.clbc.2018.03.014","volume":"18","author":"J Cortes","year":"2018","unstructured":"Cortes J, Perez-Garcia J, Whiting S, Wan Y, Solem C, Tai MH, et al. Quality-adjusted survival with nab-paclitaxel versus standard paclitaxel in metastatic breast cancer: a Q-TWiST analysis. Clin Breast Cancer. 2018;18(5):e919\u2013e26. https:\/\/doi.org\/10.1016\/j.clbc.2018.03.014.","journal-title":"Clin Breast Cancer"},{"issue":"3","key":"8446_CR35","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1111\/j.1743-7563.2009.01235.x","volume":"5","author":"Z-Z Guan","year":"2009","unstructured":"Guan Z-Z, Li QL, Feng F, et al. Superior efficacy of a Cremophor-free albumin-bound paclitaxel compared with solvent-based paclitaxel in Chinese patients with metastatic breast cancer. Asia\u2013Pacific J Clin Oncol. 2009;5(3):165\u201374. https:\/\/doi.org\/10.1111\/j.1743-7563.2009.01235.x.","journal-title":"Asia\u2013Pacific J Clin Oncol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-021-08446-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-021-08446-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-021-08446-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,30]],"date-time":"2021-06-30T11:06:33Z","timestamp":1625051193000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-021-08446-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,30]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["8446"],"URL":"https:\/\/doi.org\/10.1186\/s12885-021-08446-8","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,30]]},"assertion":[{"value":"10 November 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"QZ is a salaried employee of Eisai Inc. YS was a salaried employee of Eisai Inc. at the time of the study. RH, BN, KM, MB, and AK are salaried employees of Evidera, which received funding from Eisai Inc. to conduct the study and develop the manuscript; they are not allowed to accept remuneration from any clients for their services. IC acted as a paid consultant to Eisai Inc. for this work.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"758"}}